Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Frequently asked questions
What sector does Indaptus Therapeutics Inc (INDP) operate in?
Indaptus Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Indaptus Therapeutics Inc (INDP) current stock price?
As of the latest data, Indaptus Therapeutics Inc stock price is $3.31, with a previous close of $3.34. Indaptus Therapeutics Inc lost -$0.04 in the last trading session, representing a -1.05% loss.
What is Indaptus Therapeutics Inc (INDP) current market capitalization?
Indaptus Therapeutics Inc market cap is approximately 440.37 million.
What is Indaptus Therapeutics Inc (INDP) Earnings Per Share (EPS)?
The trailing EPS is -$3.56, and the forward EPS is -$4.48.
What is Indaptus Therapeutics Inc (INDP) EBITDA?
Indaptus Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -1.82 million.
Does Indaptus Therapeutics Inc (INDP) pay dividends?
No. Indaptus Therapeutics Inc does not pay a dividend.
When is Indaptus Therapeutics Inc (INDP) next earnings report?
Indaptus Therapeutics Inc is expected to release its next earnings report on September 30, 2026.
What is Indaptus Therapeutics Inc (INDP) beta (volatility) score?
Indaptus Therapeutics Inc has a beta of 1.171, meaning its volatility is roughly in line with the market.
